Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II PF-03446962 monotherapy in relapsed or refractory urothelial cancer
2011-005983-12Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascrinvacumab in transitional cell carcinoma (TCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: 2-month progression-free survival rate. Started Mar 2012; status: completed.
02
Drugs
ascrinvacumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2011-005983-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005983-12.